A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

NCT ID: NCT02414516


Title
A Phase 1a Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
Purpose
This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.
Details
Conditions
Solid Tumor
Keywords
Epigenetic, HDAC, Histone, Acetylation
Source
Oncolys BioPharma Inc
Sponsors
Oncolys BioPharma Inc
Status
Recruiting
Acronym
Last Updated
08 Apr 2015
URL
Official Link
Locations
United States